Analysis

  • Lonafarnib, a hope for progeria treatment

    Lonafarnib has emerged as a potential treatment for progeria and progeroid laminopathies, an ultra-rare condition for which no approved treatment exists. Having successfully demonstrated survival benefits in progeria patients, lonafarnib...

  • May’s top news stories

    Takeda Pharmaceutical has signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up to $5.3bn, and The UK’s NHS has signed a managed...

Close
Close
Close

Go Top